Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

MacDonald, John K; Nguyen, Tran M; Khanna, Reena; Timmer, Antje

doi:10.1002/14651858.cd007572.pub3

Cited by 53 publications

(47 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was approved for the treatment of patients with moderate-to-severe CD who have failed or were intolerant to treatment with corticosteroids, immunosuppressives, or anti-TNF therapy. Ustekinumab has shown to be effective in inducing and maintaining remission [29,30], with higher response rates in TNF-naïve than in TNF-experienced patients (54-58% vs. 34%, respectively) [31]. In the updated ECCO guideline [13], ustekinumab has an expanded position within the approved biologicals as it can also be used as a first-line biological -such as vedolizumab.…”

Section: Medical Therapy For CDmentioning

confidence: 99%

Treatment Algorithms for Crohn’s Disease

Sulz

Burri

Michetti³

et al. 2020

Digestion

View full text Add to dashboard Cite

Background: Treatment of Crohn's disease (CD) patients is complex as therapy choices depend on a variety of factors, such as location and severity of inflammation, disease behavior (inflammatory, stricturing or penetrating) but also comorbidities, extra-intestinal manifestations, the patient's age, and previous therapies. Subsequently, the choice of treatment should be tailored to the individual patient. Summary: This article gives the reader therapy algorithms as a guide through different CD scenarios to support the physician's decision making. New compounds introduced in CD therapy in recent years justify such an update on standard approaches. Ustekinumab and vedolizumab and their positions within the treatment options are discussed. Fistulizing perianal disease and postoperative medical prophylaxis are depicted in separate chapters with own algorithms. Key Messages: In recent years, a variety of new drugs became available to treat patients with CD-especially those who are antitumor necrosis factor (TNF) experienced with ongoing inflammation. The definitive role of vedolizumab and ustekinumab is not yet fully clarified. However, with the advantage of good safety profiles over TNF-inhibitors, these drugs will be more frequently used in the near future, also as first-line biologicals, compared to TNF-inhibitors. Concerning treatment of fistulizing disease, the knowledge of the exact anatomy of the fistula is of major importance. An interdisciplinary discussion involving gastroenterologists, surgeons, and in some cases gynecologists may help to optimize the treatment plan. Regarding the postsurgical setting in CD patients, according to the very recent Cochrane Network meta-analysis, mesalazine should be at least positioned equivalent to thiopurines and TNF-inhibitors, as shown in our algorithm.

show abstract

Section: Medical Therapy For CDmentioning

confidence: 99%

Treatment Algorithms for Crohn’s Disease

Sulz

Burri

Michetti³

et al. 2020

Digestion

View full text Add to dashboard Cite

show abstract

“…19 Although no reviews reported using a citation index for backward citation searching, only three reviews (2%) explicitly stated that a manual approach was used. 38,48,59 Reports of citation searching in some reviews used phrases suggestive of manual checking rather than a citation index, such as "we scanned the reference lists of relevant studies," but we felt this was still not fully transparent. Hence, these are recorded as manual (assumed) in Table 4.…”

Section: Reporting Of Citation Searchingmentioning

confidence: 99%

Conduct and reporting of citation searching in Cochrane systematic reviews: A cross‐sectional study

Briscoe

Bethel

Rogers

2019

Research Synthesis Methods

View full text Add to dashboard Cite

Background The search for studies for a systematic review should be conducted systematically and reported transparently to facilitate reproduction. This study aimed to report on the conduct and reporting of backward citation searching (ie, checking reference lists) and forward citation searching in a cross section of Cochrane reviews. Citation searching uses the citation network surrounding a source study to identify additional studies. Methods Cochrane reviews were identified by searching the Cochrane Database of Systematic Reviews using the wildcard symbol and date limiting to the 3‐month period November 2016 to January 2017. Cochrane reviews thus identified were screened for mention of citation searching. Descriptive detail on the conduct and reporting of citation searching was captured in data extraction forms and described and evaluated. Results Two hundred fifteen Cochrane reviews were identified. One hundred seventy‐two reviews reported backward citation searching, and 18 reviews reported forward citation searching. Web of Science was the most frequently reported citation index. The studies used for backward citation searching consisted mainly of studies meeting the inclusion criteria. One‐third of reviews that reported forward citation searching used selected studies of importance. Reporting of citation searching was compliant with the Methodological Expectations of Cochrane Intervention Reviews (MECIR) standards, but full transparency requires additional detail that only a minority of reviews reported. Conclusion The conduct of backward citation searching was more uniform than forward citation searching. This might be due to lack of MECIR guidance for forward citation searching. Reporting was generally compliant with MECIR, but this is not always sufficient to ensure full transparency.

show abstract

“…[164][165][166] In an SR&MA of these 4 trials (n ¼ 1947), ustekinumab was significantly better than placebo for the outcome of failure to achieve remission (RR, 0.91; 95% CI, 0.86-0.95). 167 Two RCTs were conducted in patients who had previously failed anti-TNF therapy. 164,165 In CERTIFI, there were no significant differences in remission rates at week 6, despite ustekinumab being associated with a higher response rate compared to placebo.…”

Section: Non-anti-tumor Necrosis Factor Biologic Therapymentioning

confidence: 99%

“…164 In the SR&MA, there were no significant differences in the rates of adverse events, serious adverse events, or withdrawals due to adverse events. 167 No RCTs assessing ustekinumab in pediatric patients with CD were found.…”

Section: Non-anti-tumor Necrosis Factor Biologic Therapymentioning

confidence: 99%